DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more


Nutrilib.com
A comprihensive source of nutritional information

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cardiac Toxicity; Sarcoma

Intervention: cisplatin (Drug); dexrazoxane hydrochloride (Drug); doxorubicin hydrochloride (Drug); etoposide (Drug); ifosfamide (Drug); methotrexate (Drug); conventional surgery (Procedure)

Phase: Phase 3

Status: Completed

Sponsored by: Children's Oncology Group

Official(s) and/or principal investigator(s):
Cindy Schwartz, MD, Study Chair, Affiliation: Sidney Kimmel Comprehensive Cancer Center

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase III trial to study the effectiveness of three combination chemotherapy regimens plus dexrazoxane in treating patients who have newly diagnosed nonmetastatic osteosarcoma.

Clinical Details

Official title: Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study

Study design: Treatment

Detailed description: OBJECTIVES: I. Compare the efficacy of three intensification regimens (doxorubicin vs doxorubicin plus ifosfamide vs doxorubicin plus ifosfamide and etoposide) in patients with newly diagnosed, previously untreated, nonmetastatic osteosarcoma. II. Determine the effect of postoperative dose intensification on outcome in patients with standard response to preoperative chemotherapy. III. Determine the effect of dexrazoxane cardioprotection during standard induction therapy on histologic response in these patients. IV. Evaluate biological factors that may predict outcome in these patients. V. Determine the safety of dexrazoxane administered with doxorubicin in combination with cisplatin or cisplatin and ifosfamide in these patients. VI. Determine the effect of dexrazoxane on cytotoxicity as measured by tumor necrosis at definitive surgery in these patients. VII. Assess the feasibility of administering doxorubicin with dexrazoxane cardioprotection or high dose ifosfamide with etoposide to standard risk patients who are also receiving methotrexate and cisplatin.

OUTLINE: This is a multicenter study. Patients are enrolled sequentially on 1 of 3 pilot intensification regimens. After surgery to completely remove the primary tumor, patients are assigned to 1 of 2 adjuvant chemotherapy groups based on percent necrosis at limb salvage. Pilot 1: (Closed to accrual as of 6/2/2000) Patients receive dexrazoxane IV followed immediately by doxorubicin IV over 20 minutes plus cisplatin IV over 4 hours on days 1 and 2 of weeks 1 and 6. Methotrexate IV over 4 hours is administered on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin for 6 courses. Pilot 2: Patients receive preoperative therapy comprised of dexrazoxane, doxorubicin, and methotrexate as in pilot 1. Ifosfamide IV over 4 hours is also administered on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane, and doxorubicin as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane, and doxorubicin as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29. Pilot 3: (Open to accrual as of 6/2/2000) Patients receive preoperative therapy comprised of methotrexate, dexrazoxane, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane and doxorubicin are administered on weeks 17, 20, 30, and 33. Patients are followed every 3 months for 1 year, every 6 months for 4 years and then annually thereafter.

PROJECTED ACCRUAL: Approximately 180 patients will be accrued for this study within 2 years.

Eligibility

Minimum age: N/A. Maximum age: 30 Years. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS: Histologically proven newly diagnosed moderate or high grade osteosarcoma without metastases No prior treatment, including complete resection No parosteal or periosteal sarcoma No osteosarcoma associated with Paget's disease No nonresectable tumors or tumors that may result in marginal or interlesion resection Must be enrolled on protocol POG-9851

PATIENT CHARACTERISTICS: Age: 30 and under Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1. 5 times normal SGOT no greater than 3 times normal Renal: Creatinine normal Phosphate at least 3. 0 mg/dL without supplementation Cardiovascular: Shortening fraction at least 28% by echocardiogram If echocardiogram unsatisfactory, must have ejection fraction at least 50% No history of pericarditis or myocarditis No symptomatic arrhythmia or symptomatic cardiac conduction disturbances

PRIOR CONCURRENT THERAPY: See Disease Characteristics Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics

Locations and Contacts

Academisch Ziekenhuis Groningen, Groningen 9713 EZ, Netherlands

San Jorge Childrens Hospital, Santurce 00912, Puerto Rico

Clinique de Pediatrie, Geneva 1211, Switzerland

Swiss Pediatric Oncology Group Bern, Bern CH 3010, Switzerland

MBCCOP - Gulf Coast, Mobile, Alabama 36688, United States

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama 35294-3300, United States

Alberta Children's Hospital, Calgary, Alberta T2T 5C7, Canada

Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada

Arizona Cancer Center, Tucson, Arizona 85724, United States

University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States

British Columbia Children's Hospital, Vancouver, British Columbia V6H 3V4, Canada

Children's Hospital and Health Center, San Diego, California 92123-4282, United States

Children's Hospital Los Angeles, Los Angeles, California 90027-0700, United States

Children's Hospital of Orange County, Orange, California 92868, United States

David Grant Medical Center, Travis Air Force Base, California 94535, United States

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095-1781, United States

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California 95051-5386, United States

Kaiser Permanente-Southern California Permanente Medical Group, San Diego, California 92120, United States

Long Beach Memorial Medical Center, Long Beach, California 90806, United States

Lucile Packard Children's Hospital at Stanford, Palo Alto, California 94304, United States

Sutter Cancer Center, Sacramento, California 95816, United States

UCSF Cancer Center and Cancer Research Institute, San Francisco, California 94143-0128, United States

University of California Davis Medical Center, Sacramento, California 95817, United States

University of California San Diego Cancer Center, La Jolla, California 92093-0658, United States

Children's Hospital of Denver, Denver, Colorado 80218, United States

Yale Comprehensive Cancer Center, New Haven, Connecticut 06520-8028, United States

Children's National Medical Center, Washington, District of Columbia 20010-2970, United States

Walter Reed Army Medical Center, Washington, District of Columbia 20307-5000, United States

All Children's Hospital, St. Petersburg, Florida 33701, United States

Baptist Hospital of Miami, Miami, Florida 33176-2197, United States

CCOP - Florida Pediatric, Tampa, Florida 33682-7757, United States

Miami Children's Hospital, Miami, Florida 33155, United States

Nemours Children's Clinic, Jacksonville, Florida 32207, United States

Shands Hospital and Clinics, University of Florida, Gainesville, Florida 32610-100277, United States

St. Mary's Hospital, West Palm Beach, Florida 33407, United States

Sylvester Cancer Center, University of Miami, Miami, Florida 33136, United States

Walt Disney Memorial Cancer Institute, Orlando, Florida 32803, United States

Emory University Hospital - Atlanta, Atlanta, Georgia 30322, United States

Cancer Research Center of Hawaii, Honolulu, Hawaii 96813, United States

Tripler Army Medical Center, Honolulu, Hawaii 96859-5000, United States

CCOP - Illinois Oncology Research Association, Peoria, Illinois 61602, United States

Children's Memorial Hospital, Chicago, Chicago, Illinois 60614, United States

Hope Children's Hospital, Oak Lawn, Illinois 60453, United States

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, United States

Saint Jude Midwest Affiliate, Peoria, Illinois 61637, United States

University of Chicago Cancer Research Center, Chicago, Illinois 60637-1470, United States

Indiana University Cancer Center, Indianapolis, Indiana 46202-5289, United States

Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa 52242-1009, United States

CCOP - Wichita, Wichita, Kansas 67214-3882, United States

University of Kansas Medical Center, Kansas City, Kansas 66160-7357, United States

Via Christi Regional Medical Center, Wichita, Kansas 67214, United States

CCOP - Ochsner, New Orleans, Louisiana 70121, United States

MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana 70112, United States

Tulane University School of Medicine, New Orleans, Louisiana 70112, United States

Eastern Maine Medical Center, Bangor, Maine 04401, United States

Maine Children's Cancer Program, Portland, Maine 04101, United States

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-2410, United States

Boston Floating Hospital Infants and Children, Boston, Massachusetts 02111, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, United States

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts 01655, United States

CCOP - Kalamazoo, Kalamazoo, Michigan 49007-3731, United States

Children's Hospital of Michigan, Detroit, Michigan 48201, United States

Hurley Medical Center, Flint, Michigan 48503, United States

St. John's Hospital and Medical Center, Detroit, Michigan 48236, United States

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0752, United States

Mayo Clinic Cancer Center, Rochester, Minnesota 55905, United States

University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, United States

Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi 39534-2576, United States

University of Mississippi Medical Center, Jackson, Mississippi 39216-4505, United States

Cardinal Glennon Children's Hospital, Saint Louis, Missouri 63104, United States

Children's Mercy Hospital, Kansas City, Missouri 64108, United States

University of Missouri-Columbia Hospital and Clinics, Columbia, Missouri 65212, United States

Washington University School of Medicine, Saint Louis, Missouri 63110, United States

University of Nebraska Medical Center, Omaha, Nebraska 68198-3330, United States

Norris Cotton Cancer Center, Lebanon, New Hampshire 03756-0002, United States

Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, United States

CCOP - Northern New Jersey, Hackensack, New Jersey 07601, United States

Hackensack University Medical Center, Hackensack, New Jersey 07601, United States

University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, United States

Herbert Irving Comprehensive Cancer Center, New York, New York 10032, United States

Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States

Mount Sinai School of Medicine, New York, New York 10029, United States

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York 10016, United States

Roswell Park Cancer Institute, Buffalo, New York 14263-0001, United States

Schneider Children's Hospital, New Hyde Park, New York 11042, United States

State University of New York - Upstate Medical University, Syracuse, New York 13210, United States

State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York 11790-7775, United States

University of Rochester Cancer Center, Rochester, New York 14642, United States

Carolinas Medical Center, Charlotte, North Carolina 28232-2861, United States

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina 27157-1082, United States

Duke Comprehensive Cancer Center, Durham, North Carolina 27710, United States

East Carolina University School of Medicine, Greenville, North Carolina 27858-4354, United States

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina 27599-7295, United States

Mission Saint Joseph's Health System, Asheville, North Carolina 28801, United States

Presbyterian Healthcare, Charlotte, North Carolina 28233-3549, United States

CCOP - Merit Care Hospital, Fargo, North Dakota 58122, United States

Veterans Affairs Medical Center - Fargo, Fargo, North Dakota 58102, United States

IWK Health Centre, Halifax, Nova Scotia B3J 3G9, Canada

Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio 45229-3039, United States

Children's Hospital of Columbus, Columbus, Ohio 43205-2696, United States

Ireland Cancer Center, Cleveland, Ohio 44106-5065, United States

Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma 74136, United States

Oklahoma Memorial Hospital, Oklahoma City, Oklahoma 73126-0307, United States

Children's Hospital, Hamilton, Ontario L8N 3Z5, Canada

Children's Hospital of Eastern Ontario, Ottawa, Ontario K1H 8L1, Canada

Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

CCOP - Columbia River Program, Portland, Oregon 97213, United States

Doernbecher Children's Hospital, Portland, Oregon 97201-3098, United States

Legacy Emanuel Hospital and Health Center, Portland, Oregon 97227, United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, United States

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134-1095, United States

Centre Hospitalier de L'Universite Laval, Sainte Foy, Quebec GIV 4G2, Canada

Hopital Sainte Justine, Montreal, Quebec H3T 1C5, Canada

McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec H3H 1P3, Canada

Children's Hospital of Greenville Hospital System, Greenville, South Carolina 29605, United States

Medical University of South Carolina, Charleston, South Carolina 29425-0721, United States

James H. Quillen College of Medicine, Johnson City, Tennessee 37614-0622, United States

Saint Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, United States

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6838, United States

Baylor College of Medicine, Houston, Texas 77030, United States

MBCCOP - South Texas Pediatric, San Antonio, Texas 78229-3900, United States

Medical City Dallas Hospital, Dallas, Texas 75230, United States

San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas 78236-5300, United States

Scott and White Clinic, Temple, Texas 76508, United States

Simmons Cancer Center - Dallas, Dallas, Texas 75235-9154, United States

Texas Oncology P.A., Dallas, Texas 75230-2503, United States

University of Texas - MD Anderson Cancer Center, Houston, Texas 77030-4009, United States

University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7811, United States

University of Texas Medical Branch, Galveston, Texas 77555-0209, United States

Vermont Cancer Center, Burlington, Vermont 05401-3498, United States

Royal Children's Hospital, Parkville, Victoria 3052, Australia

Cancer Center at the University of Virginia, Charlottesville, Virginia 22908, United States

Carilion Roanoke Community Hospital, Roanoke, Virginia 24029, United States

Inova Fairfax Hospital, Falls Church, Virginia 22042-3300, United States

Massey Cancer Center, Richmond, Virginia 23298-0037, United States

Naval Medical Center, Portsmouth, Portsmouth, Virginia 23708-2197, United States

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington 98105, United States

Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, United States

Madigan Army Medical Center, Tacoma, Washington 98431-5000, United States

West Virginia University Hospitals, Morgantown, West Virginia 26506-9300, United States

West Virginia University Medical School-Charleston, Charleston, West Virginia 25304, United States

Princess Margaret Hospital for Children, Perth, Western Australia 6001, Australia

Midwest Children's Cancer Center, Milwaukee, Wisconsin 53226, United States

St. Vincent Hospital, Green Bay, Wisconsin 54307-3508, United States

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792-6164, United States

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: September 1999
Last updated: May 23, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008